Roivant Sciences Ltd. $ROIV Shares Acquired by Inceptionr LLC

Inceptionr LLC raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 98.0% in the third quarter, HoldingsChannel.com reports. The fund owned 66,059 shares of the company’s stock after buying an additional 32,703 shares during the quarter. Inceptionr LLC’s holdings in Roivant Sciences were worth $999,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its position in Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the period. Envestnet Asset Management Inc. increased its position in Roivant Sciences by 30.2% in the second quarter. Envestnet Asset Management Inc. now owns 42,810 shares of the company’s stock worth $482,000 after buying an additional 9,936 shares during the period. Bank of New York Mellon Corp lifted its stake in Roivant Sciences by 12.7% in the second quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock valued at $50,787,000 after buying an additional 506,219 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its stake in Roivant Sciences by 330.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 104,458 shares of the company’s stock valued at $1,177,000 after buying an additional 80,206 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Activity at Roivant Sciences

In related news, CEO Matthew Gline sold 1,740,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the transaction, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. The trade was a 9.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel Allen Gold sold 917,282 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $23.04, for a total transaction of $21,134,177.28. Following the completion of the transaction, the director directly owned 17,130,445 shares in the company, valued at $394,685,452.80. This trade represents a 5.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,118,014 shares of company stock worth $311,557,023. Company insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ROIV. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. The Goldman Sachs Group raised their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. HC Wainwright upped their target price on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Guggenheim upped their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.81.

Roivant Sciences Price Performance

ROIV stock opened at $29.53 on Tuesday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $30.03. The company’s 50 day simple moving average is $24.72 and its 200-day simple moving average is $20.28. The firm has a market capitalization of $21.13 billion, a P/E ratio of -25.24 and a beta of 1.17.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.